房颤卒中后早期与延迟抗凝治疗比较
该研究为研究者发起的开放标签试验,在15个国家103个中心纳入2013例房颤急性缺血性卒中患者(37%轻型、40%中型、23%重型),随机分配至早期抗凝(轻型或中型卒中48小时内,重型卒中第6或7天)或延迟抗凝(轻型第3或4天,中型第6或7天,重型第12、13或14天)。主要终点为随机化后30天内复发性缺血性卒中、系统性栓塞、严重颅外出血、症状性颅内出血或血管性死亡的复合终点。早期组29例(2.9%)、延迟组41例(4.1%)发生主要终点事件,风险差异-1.18个百分点(95%CI -2.84至0.47)。复发性缺血性卒中30天时早期组14例(1.4%)vs延迟组25例(2.5%)(OR 0.57,95%CI 0.29至1.07),90天时分别为18例(1.9%)和30例(3.1%)(OR 0.60,95%CI 0.33至1.06)。症状性颅内出血两组30天内均为2例(0.2%)。
要点
- 房颤急性缺血性卒中后早期(轻型/中型48小时内,重型第6或7天)启动DOAC,30天复合终点事件风险差异-1.18个百分点(95%CI -2.84至0.47),未达统计学显著。
- 复发性缺血性卒中30天时早期组1.4% vs延迟组2.5%(OR 0.57,95%CI 0.29至1.07),90天时1.9% vs 3.1%(OR 0.60,95%CI 0.33至1.06),均未达统计学显著。
- 症状性颅内出血30天内两组均为0.2%(各2例),无差异。
- 主要终点30天发生率早期组2.9% vs延迟组4.1%,风险差异-1.18个百分点(95%CI -2.84至0.47)。
适用人群与场景
- 房颤合并急性缺血性卒中的患者,卒中严重程度为轻型(37%)、中型(40%)或重型(23%)。
处置流程与药物剂量
- 早期抗凝组:轻型或中型卒中在48小时内启动DOAC,重型卒中在第6或7天启动。
- 延迟抗凝组:轻型卒中在第3或4天启动DOAC,中型卒中在第6或7天启动,重型卒中在第12、13或14天启动。
研究设计与关键结果
- 研究类型:研究者发起的开放标签随机对照试验,在15个国家103个中心进行,纳入2013例患者,早期抗凝组1006例,延迟抗凝组1007例。
- 主要终点(30天内复发性缺血性卒中、系统性栓塞、严重颅外出血、症状性颅内出血或血管性死亡的复合终点):早期组29例(2.9%)vs延迟组41例(4.1%),风险差异-1.18个百分点(95%CI -2.84至0.47)。
- 复发性缺血性卒中30天:早期组14例(1.4%)vs延迟组25例(2.5%),OR 0.57(95%CI 0.29至1.07)。
- 复发性缺血性卒中90天:早期组18例(1.9%)vs延迟组30例(3.1%),OR 0.60(95%CI 0.33至1.06)。
- 症状性颅内出血30天:两组均为2例(0.2%)。
证据类型、等级与局限
- 证据类型:随机对照试验(开放标签,评估者盲法)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:基于95%CI,早期与延迟使用DOAC相比,30天复合终点事件发生率估计范围从低2.8个百分点至高0.5个百分点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effect of early as compared with later initiation of direct oral anticoagulants (DOACs) in persons with atrial fibrillation who have had an acute ischemic stroke is unclear.
METHODS: We performed an investigator-initiated, open-label trial at 103 sites in 15 countries. Participants were randomly assigned in a 1:1 ratio to early anticoagulation (within 48 hours after a minor or moderate stroke or on day 6 or 7 after a major stroke) or later anticoagulation (day 3 or 4 after a minor stroke, day 6 or 7 after a moderate stroke, or day 12, 13, or 14 after a major stroke). Assessors were unaware of the trial-group assignments. The primary outcome was a composite of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death within 30 days after randomization. Secondary outcomes included the components of the composite primary outcome at 30 and 90 days.
RESULTS: Of 2013 participants (37% with minor stroke, 40% with moderate stroke, and 23% with major stroke), 1006 were assigned to early anticoagulation and 1007 to later anticoagulation. A primary-outcome event occurred in 29 participants (2.9%) in the early-treatment group and 41 participants (4.1%) in the later-treatment group (risk difference, -1.18 percentage points; 95% confidence interval [CI], -2.84 to 0.47) by 30 days. Recurrent ischemic stroke occurred in 14 participants (1.4%) in the early-treatment group and 25 participants (2.5%) in the later-treatment group (odds ratio, 0.57; 95% CI, 0.29 to 1.07) by 30 days and in 18 participants (1.9%) and 30 participants (3.1%), respectively, by 90 days (odds ratio, 0.60; 95% CI, 0.33 to 1.06). Symptomatic intracranial hemorrhage occurred in 2 participants (0.2%) in both groups by 30 days.
CONCLUSIONS: In this trial, the incidence of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death at 30 days was estimated to range from 2.8 percentage points lower to 0.5 percentage points higher (based on the 95% confidence interval) with early than with later use of DOACs. (Funded by the Swiss National Science Foundation and others; ELAN ClinicalTrials.gov number, NCT03148457.).
参考来源
- Fischer U, Koga M, Strbian D, et al. Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. N Engl J Med. 2023. PMID: 37222476. doi:10.1056/NEJMoa2303048
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。